FBIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

14.53M

-2.43%

21.02M

+43.68%

18.80M

+24.34%

Estimates Revision

The market is revising Downward the revenue expectations for Fortress Biotech, Inc. (FBIO) for FY2025, with the revenue forecasts being adjusted by -11.5% over the past three months. During the same period, the stock price has changed by 53.57%.

Revenue Estimates for FY2025

Revise Downward

-11.5%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-93.82%

In Past 3 Month

Stock Price

Go Up

+53.57%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.75 USD with a low forecast of 4.50 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.50

Averages

10.75

High

17.00

Current: 0.000

Low

4.50

Averages

10.75

High

17.00

Alliance Global

Scott Henry

Buy

maintain

2025-11-19

Reason

Alliance Global

Scott Henry

Price Target

2025-11-19

maintain

Buy

Reason

Alliance Global analyst Scott Henry raised the firm's price target on Fortress Biotech to $4.50 from $4 and keeps a Buy rating on the shares following the Q3 report. The company's operating expenses are lower now in the absence of Checkpoint, the analyst tells investors in a research note.

H.C. Wainwright

Joseph Pantginis

Buy

downgrade

$26 -> $17

2025-08-21

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$26 -> $17

2025-08-21

downgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Fortress Biotech to $17 from $26 and keeps a Buy rating on the shares. The firm updated the company's model.

Roth Capital

Buy

downgrade

$15 -> $12

2025-08-19

Reason

Roth Capital

Price Target

$15 -> $12

2025-08-19

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on Fortress Biotech to $12 from $15 and keeps a Buy rating on the shares after its Q2 results. The firm notes that with Journey's Emrosi launched, the recently completed sale of Checkpoint and a September PDUFA for CUTX-101, Fortress is well positioned to become a self-funding entity, the analyst tells investors in a research note. Roth adds however that its lower price target reflects a higher share count, lower market capitalizations of the company's public company portfolio, and lower probability of previously anticipated approval timing for CAEL-101.

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$15 → $16

2025-03-11

Reason

Roth MKM

Jason Wittes

Price Target

$15 → $16

2025-03-11

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Fortress Biotech Inc (FBIO.O) is -2.50, compared to its 5-year average forward P/E of -3.37. For a more detailed relative valuation and DCF analysis to assess Fortress Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.37

Current PE

-2.50

Overvalued PE

2.09

Undervalued PE

-8.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.68

Current EV/EBITDA

-1.03

Overvalued EV/EBITDA

0.21

Undervalued EV/EBITDA

-1.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.39

Current PS

1.27

Overvalued PS

2.71

Undervalued PS

0.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FBIO News & Events

Events Timeline

No data

News

9.0

2025-12-20NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

9.0

2025-12-15Globenewswire

Fortress Biotech's CUTX-101 NDA Resubmission Accepted by FDA with Target Date of January 14, 2026

9.0

2025-12-15Newsfilter

Fortress Biotech's CUTX-101 NDA Resubmission Accepted by FDA with Target Date of January 14, 2026

People Also Watch

Frequently Asked Questions

What is Fortress Biotech Inc (FBIO) stock price today?

The current price of FBIO is 4.3 USD — it has decreased -1.83 % in the last trading day.

What is Fortress Biotech Inc (FBIO)'s business?

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

What is the price predicton of FBIO Stock?

What is Fortress Biotech Inc (FBIO)'s revenue for the last quarter?

Fortress Biotech Inc revenue for the last quarter amounts to 17.63M USD, increased 20.52 % YoY.

What is Fortress Biotech Inc (FBIO)'s earnings per share (EPS) for the last quarter?

Fortress Biotech Inc. EPS for the last quarter amounts to 0.11 USD, decreased -114.47 % YoY.

What changes have occurred in the market's expectations for Fortress Biotech Inc (FBIO)'s fundamentals?

How many employees does Fortress Biotech Inc (FBIO). have?

Fortress Biotech Inc (FBIO) has 101 emplpoyees as of January 10 2026.

What is Fortress Biotech Inc (FBIO) market cap?

Today FBIO has the market capitalization of 133.46M USD.